GlassScriptPhysician profile
Brittnee Beck
NPI 1407546021
$3,019.29
in general payments reported to CMS, 2019-2025
29 companies · $1,022 in 2025
The $1,022 reported for 2025 was more than what 85% of Adult Health (Nurse Practitioner) providers received nationally (typical 2025 total: $182).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $721 · 2024: $1,276 · 2025: $1,022.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,019.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,019.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $601.02 | 2023-2024 | Invega Sustenna, Spravato |
| Alkermes, INC. | $501.28 | 2023-2024 | Aristada, Lybalvi, Aristada Initio |
| Abbvie INC. | $288.23 | 2023-2025 | |
| Otsuka America Pharmaceutical, INC. | $196.28 | 2023-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Pfizer INC. | $193.79 | 2025 | |
| Lilly USA, LLC | $183.16 | 2025 | Mounjaro, Jardiance, Zepbound |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $125.36 | 2024-2025 | Caplyta |
| Neurocrine Biosciences, INC. | $123.19 | 2023-2024 | Ingrezza |
| Vanda Pharmaceuticals INC. | $111.22 | 2024-2025 | Fanapt |
| Amgen INC. | $87.69 | 2025 | Repatha, Evenity, Otezla |
| Astrazeneca Pharmaceuticals LP | $84.15 | 2025 | Airsupra, Breztri, Farxiga |
| Teva Pharmaceuticals USA, INC. | $73.71 | 2023-2024 | Uzedy |
| Lundbeck LLC | $67.91 | 2024-2025 | Rexulti |
| Axsome Therapeutics, INC. | $54.97 | 2024-2025 | Auvelity |
| Bayer Healthcare Pharmaceuticals INC. | $48.39 | 2025 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Indivior INC. | $43.65 | 2023-2024 | Perseris |
| Phathom Pharmaceuticals, INC. | $33.16 | 2025 | Voquezna |
| Ironshore Pharmaceuticals INC. | $23.96 | 2023 | Jornay Pm |
| Shield Therapeutics INC | $23.91 | 2025 | |
| Inspire Medical Systems, INC. | $18.27 | 2025 | Inspire |
| Averitas Pharma INC. | $18.09 | 2024 | Qutenza |
| Exact Sciences Corporation | $18.06 | 2024 | Cologuard Collection Kit |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $17.06 | 2025 | Xifaxan |
| Almatica Pharma LLC | $16.94 | 2023 | Loreev Xr |
| Novo Nordisk INC | $16.81 | 2025 | Ozempic |
| Boehringer Ingelheim Pharmaceuticals, INC. | $16.61 | 2024 | Jardiance |
| E.R. Squibb & Sons, L.L.C. | $16.21 | 2024 | |
| Sumitomo Pharma America, INC. | $14.14 | 2025 | Gemtesa |
| Corium, LLC | $2.07 | 2024 | Azstarys |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brittnee Beck listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.